An error appeared in the article “Estimating the Risk for Alpha-1 Antitrypsin Deficiency among COPD Patients: Evidence Supporting Targeted Screening” (vol. 3, no. 3, p. 136) by Frederick J. de Serres, Ignacio Blanco, and Enrique Fernández-Bustillo. A percentage that should have been listed as 0.6% was incorrectly listed as 6.1%. The corrected paragraph appears here:
Another estimate of interest is the 0.6% of AAT Deficient subjects of pheontype PISZ and PIZZ estimated in the population of 19.3 million white COPD patients ([117,869/19.3 million)]*100). If we also include the number of AAT Deficient subjects with phenotype PIMZ, this percentage increases to 9.5% [1,829,673/19.3 million]*100), whereas the number of AAT Deficient subjects of phenotype PIMZ alone is 8.9% ([1,711,804/19.3 million]*100).